转移性肾细胞癌和骨转移患者的管理。
Management of Patients With Metastatic Renal Cell Cancer and Bone Metastases.
机构信息
Department of Oncology and Palliative Medicine, Nordland Hospital, Bodø, Norway
Department of Clinical Medicine, Faculty of Health Sciences, University of Tromsø, Tromsø, Norway.
出版信息
In Vivo. 2020 Mar-Apr;34(2):675-678. doi: 10.21873/invivo.11822.
BACKGROUND/AIM: Previous research has suggested that patients with metastatic renal cell cancer (mRCC) and bone metastases have a poorer prognosis compared to their counterparts with no skeletal involvement. Therefore, we analyzed the management and outcomes of such patients in our center.
PATIENTS AND METHODS
We performed a retrospective study of 35 consecutive patients who received systemic treatment, largely targeted therapy, for mRCC with bone metastases.
RESULTS
The median overall survival was 25 months from the time of diagnosis of mRCC. The 5-year survival rate was 16%. Survival from diagnosis of mRCC was significantly worse in patients with bone metastases present at the start of first-line systemic therapy (median 13 months) compared to delayed metastases diagnosed later during the course of disease (46 months, p=0.01). Few patients (29%) were able to receive more than two lines of systemic therapy. Bone-only metastases were uncommon (11%).
CONCLUSION
Most patients with mRCC and bone metastases have limited overall survival.
背景/目的：先前的研究表明，转移性肾细胞癌（mRCC）伴骨转移的患者预后较无骨骼受累者差。因此，我们分析了我院此类患者的治疗方法和结局。
患者与方法
我们对 35 例连续接受 mRCC 伴骨转移系统治疗（主要为靶向治疗）的患者进行了回顾性研究。
结果
自 mRCC 诊断起的中位总生存期为 25 个月。5 年生存率为 16%。起始一线系统治疗时即存在骨转移的患者的 mRCC 诊断后生存时间显著短于疾病过程中延迟诊断的骨转移患者（中位时间 13 个月比 46 个月，p=0.01）。仅有少数患者（29%）能够接受超过二线的系统治疗。单纯骨转移并不常见（11%）。
结论
大多数 mRCC 伴骨转移患者的总体生存时间有限。
Zotero 插件